The active use of immunotherapeutic drugs against CD19 (the bispecific T-cell engager blinatumomab and T cells with chimeric antigen receptors (CAR-T)) [6,7] significantly complicates MFC-MRD monitoring because of possible CD19 downregulation by tumor cells [8,9]. Here, CD19 is linked to neoplasm.